Envoy Medical, Inc. (COCH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Envoy Medical, Inc. (COCH) trades at $0.80 with AI Score 19/100 (Grade F). Envoy Medical, Inc. focuses on developing and commercializing medical technologies for the hearing loss spectrum. Market cap: $16.55M, Sector: Healthcare.
Price live · AI analysis from May 4, 2026Analyst Coverage for COCH: COCH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates COCH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
COCH: 3/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Envoy Medical, Inc. (COCH) Healthcare & Pipeline Overview
Envoy Medical, Inc. operates in the hearing health sector, providing medical technologies such as hearing aids, middle ear implants, and cochlear implants. Founded in 1995, the company aims to address the hearing loss spectrum with innovative solutions, positioning itself within a competitive medical device market.
What Is the Investment Thesis for COCH?
Envoy Medical, Inc. presents a focused play within the medical devices sector, specifically targeting the hearing loss market. With a market capitalization of $16.55M, the company's future hinges on the successful commercialization and market penetration of its innovative hearing solutions, including the Esteem middle ear implant and Acclaim cochlear implant. Upcoming catalysts include regulatory approvals and clinical trial outcomes that could validate the efficacy and safety of its products. However, the company's negative profit margin of -9857.3% and gross margin of -262.7% highlight significant financial challenges. The high beta of 2.05 suggests considerable volatility, reflecting the speculative nature of the stock. Success will depend on effective cost management, successful product launches, and capturing market share in a competitive landscape.
Based on FMP financials and quantitative analysis
COCH Key Highlights
- Market Cap of $16.55M indicates a small-cap company with potential for high growth but also higher risk.
- Profit Margin of -9857.3% reflects significant losses and the need for improved operational efficiency.
- Gross Margin of -262.7% suggests that the cost of goods sold is substantially higher than revenue, requiring a re-evaluation of pricing and production strategies.
- Beta of 2.05 indicates higher volatility compared to the market, appealing to risk-tolerant investors.
- No Dividend Yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.
Who Are COCH's Competitors?
COCH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SONVF Sonova Holding AG | $257.67 | +2.09% | $15.31B | 52 |
| CI Cigna Corporation | $278.35 | -3.27% | $73.63B | 79 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are COCH's Key Strengths?
- Innovative product portfolio including middle ear implants.
- Established presence in the hearing health market.
- Focus on improving patient outcomes.
- Experienced leadership team.
What Are COCH's Weaknesses?
- Negative profit and gross margins.
- Limited market share compared to larger competitors.
- Dependence on regulatory approvals for new products.
- High beta indicating significant stock volatility.
What Could Drive COCH Stock Higher?
- FDA approval for new hearing aid technology.
- Clinical trial results for the Acclaim cochlear implant.
- Expansion of distribution network in key markets.
- Strategic partnerships with audiology clinics.
What Are the Key Risks for COCH?
- Financial-distress signal — its Altman Z-Score of -16.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the hearing health market.
- Regulatory hurdles and compliance requirements.
- Economic downturns affecting healthcare spending.
- Negative profit and gross margins impacting financial stability.
- Technological obsolescence.
What Are the Growth Opportunities for COCH?
- Expansion of Cochlear Implant Technology: The global cochlear implant market is projected to reach $2.4 billion by 2028, driven by technological advancements and increasing adoption rates. Envoy Medical can capitalize on this growth by enhancing its Acclaim cochlear implant technology and expanding its distribution network. Focusing on improved sound processing and user experience can differentiate Envoy Medical from competitors, potentially capturing a larger market share within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with audiology clinics and hearing healthcare providers can enhance Envoy Medical's market reach and customer acquisition. Additionally, acquiring smaller, innovative companies with complementary technologies can expand the product portfolio and accelerate growth. These partnerships can be established within the next 1-2 years, providing immediate access to established distribution channels and customer bases.
- Geographic Expansion into Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, present significant growth opportunities due to their large populations and increasing healthcare spending. Envoy Medical can enter these markets by adapting its products to local needs and establishing partnerships with local distributors. This expansion can be initiated within the next 2-3 years, targeting countries with high unmet needs for hearing healthcare.
- Development of Next-Generation Hearing Aids: The hearing aid market is continuously evolving, with advancements in digital signal processing and wireless connectivity. Envoy Medical can invest in research and development to create next-generation hearing aids that offer superior sound quality, comfort, and connectivity. These new products can be launched within the next 3-4 years, attracting a broader customer base and driving revenue growth.
- Focus on Personalized Hearing Solutions: Personalized hearing solutions, tailored to individual patient needs, are gaining traction in the market. Envoy Medical can leverage data analytics and artificial intelligence to develop customized hearing aids and implants that optimize hearing outcomes. This approach can differentiate Envoy Medical from competitors and enhance customer satisfaction, leading to increased sales and market share within the next 2-3 years.
What Opportunities Does COCH Have?
- Expansion into emerging markets.
- Development of next-generation hearing aids.
- Strategic partnerships and acquisitions.
- Increasing awareness of hearing loss and demand for advanced solutions.
What Threats Does COCH Face?
- Intense competition from established players.
- Regulatory hurdles and compliance requirements.
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
What Are COCH's Competitive Advantages?
- Proprietary Technology: Envoy Medical's Esteem middle ear implant represents a unique technology in the hearing loss market.
- Established Brand Reputation: The company has been operating since 1995, building a brand known to some audiologists.
- Specialized Product Portfolio: Envoy Medical offers a range of products covering different types and severities of hearing loss.
- Intellectual Property: Patents and trade secrets protect Envoy Medical's innovations.
What Does COCH Do?
Envoy Medical, Inc., established in 1995 and based in White Bear Lake, Minnesota, specializes in creating and distributing advanced medical technologies designed to treat various degrees of hearing loss. Originally known as St. Croix Medical, Inc., the company rebranded to Envoy Medical Corporation in December 2004, marking a strategic shift towards its current focus. Envoy Medical's product portfolio includes a range of hearing solutions, such as conventional hearing aids, the Esteem middle ear implant, bone conduction devices, and the Acclaim cochlear implant. These products cater to a diverse patient base, addressing conductive, sensorineural, and mixed hearing loss. The Esteem implant is designed to provide natural sound quality by utilizing the ear's natural mechanics, while the Acclaim cochlear implant aims to restore hearing in individuals with severe to profound hearing loss. Envoy Medical continues to innovate within the hearing health space, focusing on developing technologies that improve patient outcomes and quality of life. The company's commitment to research and development is central to its mission of providing effective and accessible hearing solutions.
What Products and Services Does COCH Offer?
- Develops and manufactures medical technologies for the hearing loss spectrum.
- Offers hearing aids for individuals with mild to moderate hearing loss.
- Provides Esteem middle ear implants for natural sound quality.
- Creates bone conduction devices for conductive hearing loss.
- Manufactures Acclaim cochlear implants for severe to profound hearing loss.
- Focuses on improving patient outcomes and quality of life through innovative hearing solutions.
How Does COCH Make Money?
- Develops and manufactures hearing health technologies.
- Sells products directly to audiologists and hearing healthcare providers.
- Generates revenue through the sale of hearing aids, middle ear implants, bone conduction devices, and cochlear implants.
- Invests in research and development to create new and improved hearing solutions.
What Industry Does COCH Operate In?
Envoy Medical, Inc. operates within the global medical devices industry, specifically targeting the hearing health market. This market is characterized by technological advancements, an aging population, and increasing awareness of hearing loss. The competitive landscape includes established players like Sonova and Cochlear, as well as smaller, innovative companies. Envoy Medical's success depends on its ability to differentiate its products through unique features and clinical outcomes. The industry is also subject to regulatory scrutiny, requiring companies to navigate complex approval processes to bring new products to market. Market growth is driven by the increasing prevalence of hearing loss and the demand for advanced hearing solutions.
Who Are COCH's Key Customers?
- Individuals with mild to moderate hearing loss.
- Individuals with severe to profound hearing loss.
- Audiologists and hearing healthcare professionals.
- Hospitals and clinics specializing in hearing health.
- Patients seeking advanced hearing solutions.
Envoy Medical, Inc. Financial Trajectory
Envoy Medical, Inc. (COCH) reported $39K in revenue for Q1 2026, a decline of 48.0% compared to the prior quarter. The company recorded a net loss of $4.4M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, COCH averaged $-0.26 in diluted EPS.
Company Profile
Envoy Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in White Bear Lake, US. The company is led by CEO Brent T. Lucas. COCH has traded publicly since 2021.
How Envoy Medical, Inc. Is Valued
Envoy Medical, Inc. carries a market capitalization of $16.55M, placing it in the micro-cap category. Relative to its peer group, COCH's quantitative score of 19/100 is below the peer average of 70/100.
ROE 239%Key Financial Metrics
Return on equity for Envoy Medical, Inc. stands at 239.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -77.5%, showing how much profit it generates from its asset base. A current ratio of 2.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Envoy Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.30 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Envoy Medical, Inc. revenue of about $200K for fiscal 2026, with EPS near $-0.30.
COCH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Envoy Medical's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively with discussions around innovative product developments and potential market expansion.
- Analysts have noted the increasing demand for hearing solutions, positioning Envoy Medical favorably within a growing industry.
- Recent partnerships have sparked optimism, aligning Envoy Medical with established players that can enhance its market reach.
Bear Case
- Concerns about regulatory hurdles have emerged, as navigating the medical device approval process can be lengthy and unpredictable.
- Social sentiment reflects skepticism regarding the company's ability to scale operations effectively in a competitive landscape.
- Recent discussions highlight potential supply chain challenges that could impact production timelines and delivery.
- Market perception remains cautious due to historical volatility in the medical device sector, which may deter some investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $39,000 | -$4M | -$0.08 |
| Q4 2025 | $75,000 | -$7M | -$0.27 |
| Q3 2025 | $42,000 | -$6M | -$0.35 |
| Q2 2025 | $78,000 | -$6M | -$0.32 |
Based on FMP financials and quantitative analysis
COCH Latest News
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Jun 10, 2026
-
Envoy Medical Q1 EPS $(0.08) Beats $(0.14) Estimate, Sales $39.000K Miss $60.000K Estimate
benzinga · May 11, 2026
-
Envoy Medical Achieves Full Enrollment Of U.S. Pivotal Clinical Study To Evaluate Fully Implanted Cochlear Implant Seeking FDA Nod
benzinga · May 11, 2026
-
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
newsfilecorp.com · May 11, 2026
COCH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COCH.
Price Targets
Wall Street price target analysis for COCH.
COCH MoonshotScore
What does this score mean?
The MoonshotScore rates COCH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Envoy Medical Q1 EPS $(0.08) Beats $(0.14) Estimate, Sales $39.000K Miss $60.000K Estimate
Envoy Medical Achieves Full Enrollment Of U.S. Pivotal Clinical Study To Evaluate Fully Implanted Cochlear Implant Seeking FDA Nod
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
Leadership: Brent T. Lucas
CEO
Brent T. Lucas serves as the Chief Executive Officer of Envoy Medical, Inc. His professional background includes experience in the medical device industry, with a focus on strategic leadership and business development. Lucas is responsible for guiding the company's overall strategy, overseeing product development, and managing relationships with key stakeholders. His expertise lies in driving innovation and commercializing medical technologies to improve patient care.
Track Record: Under Brent T. Lucas's leadership, Envoy Medical has focused on advancing its product pipeline and expanding its market presence. Key milestones include the continued development of the Acclaim cochlear implant and efforts to secure regulatory approvals for new and existing products. Lucas has also emphasized strategic partnerships to enhance the company's distribution capabilities and market reach.
Envoy Medical, Inc. Healthcare Stock: Key Questions Answered
What does Envoy Medical, Inc. do?
Envoy Medical, Inc. is a medical device company specializing in hearing health. It develops, manufactures, and markets a range of hearing solutions, including hearing aids, middle ear implants (Esteem), bone conduction devices, and cochlear implants (Acclaim). The company's mission is to provide innovative technologies that address various degrees of hearing loss, improving the quality of life for individuals with hearing impairments. Envoy Medical targets audiologists, hearing healthcare professionals, and patients seeking advanced hearing solutions.
What do analysts say about COCH stock?
As of May 4, 2026, analyst coverage of COCH stock is limited, reflecting its small-cap status and speculative nature. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative earnings. Growth considerations center on the successful commercialization of its innovative hearing solutions, particularly the Esteem middle ear implant and Acclaim cochlear implant. Analyst sentiment is contingent on regulatory approvals, clinical trial outcomes, and the company's ability to improve its financial performance.
What are the main risks for COCH?
The primary risks for Envoy Medical, Inc. include intense competition from larger, well-established players in the hearing health market, such as Sonova and Cochlear. Regulatory hurdles and compliance requirements pose significant challenges, as the company relies on FDA approvals for its products. Economic downturns could affect healthcare spending, impacting demand for its hearing solutions. Additionally, the company's negative profit and gross margins raise concerns about its financial sustainability. Technological obsolescence also presents a risk, requiring continuous innovation to stay competitive.
What are the key factors to evaluate for COCH?
Envoy Medical, Inc. (COCH) holds an AI score of 19/100 (low). Not financial advice.
How frequently does COCH data refresh on this page?
COCH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven COCH's recent stock price performance?
Envoy Medical, Inc. (COCH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio including middle ear implants. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider COCH overvalued or undervalued right now?
Valuing Envoy Medical, Inc. (COCH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying COCH?
Before investing in Envoy Medical, Inc. (COCH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of May 4, 2026.
- Financial data may be subject to change.
- Analyst opinions may vary.